{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T09:12:14Z","timestamp":1790327534968,"version":"4.1.0"},"reference-count":28,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100005897","name":"Soci\u00e9t\u00e9 Fran\u00e7aise de Dermatologie et de Pathologie Sexuellement Transmissible","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Vitiligo is a complex autoimmune skin disease characterized by loss of melanocytes resulting in the appearance of white skin patches. Recent advances in treatment have improved patient outcomes, but the process of repigmentation is prolonged and often incomplete.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the effects of early systemic intervention in newly diagnosed vitiligo patients compared to those with a longer disease duration, including both long\u2010standing and recently developed depigmented lesions, on clinical outcome, melanocytes and melanocyte precursor reservoir at lesional sites across groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Prospective bicentric interventional study. Fifty\u2010one eligible patients were enrolled in three groups depending on duration and activity of their vitiligo (G1: long\u2010lasting disease (more than 2\u2009years) with no active lesions; G2: long\u2010lasting disease with recent lesions; G3: newly diagnosed, less than 6\u2009months, with active lesions). All subjects received Nb\u2010UVB and oral mini pulse of corticosteroids twice a week for 6\u2009months. Clinical scores were used to assess extent (VES) and disease activity (V\u2010SAS). Primary objective was to compare efficacy of treatment at 6\u2009months between the groups. Secondary objectives include the analysis of melanocyte and melanocyte precursor reservoir using skin immunohistofluorescence of lesional vitiligo skin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 51 randomized patients, 44 (86%) completed the 6\u2010month assessment. Mean disease duration was 13.4\u2009years in G1, 8.3\u2009years in G2 and 4.8\u2009months in G3. VES75 (75% improvement from baseline extent of vitiligo) at 6\u2009months after treatment was achieved in 0% in G1, 16% in G2 and 46% in G3 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01). Epidermal mature melanocytes persisted in 50% of G3 patients, 20% of G2 and none of the G1 patients. All patients had remaining melanocyte precursors in the lesional skin.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Early systemic therapeutic approach allows a significantly better response in recently diagnosed patients, highlighting the importance of an early window of opportunity in vitiligo.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.70748","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T08:53:00Z","timestamp":1790326380000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Early systemic intervention for vitiligo: A prospective bicentric interventional study"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1796-2076","authenticated-orcid":false,"given":"Clemence","family":"Bertold","sequence":"first","affiliation":[{"name":"University of C\u00f4te d'Azur, C3M, INSERM U1065  Nice France"},{"name":"Department of Dermatology University of C\u00f4te d'Azur, Centre Hospitalier Universitaire de Nice (CHU)  Nice France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1139-0908","authenticated-orcid":false,"given":"Julien","family":"Seneschal","sequence":"additional","affiliation":[{"name":"University of Bordeaux, CNRS, Immuno ConcEpT, UMR 5164  Bordeaux France"},{"name":"Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin DisordersH\u00f4pital Saint\u2010Andr\u00e9, UMR 5164 CHU de Bordeaux, H\u00f4pital Saint\u2010Andr\u00e9, UMR 5164  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1849-9626","authenticated-orcid":false,"given":"Eric","family":"Fontas","sequence":"additional","affiliation":[{"name":"Department of Research and Innovation University of C\u00f4te d'Azur, Centre Hospitalier Universitaire de Nice (CHU)  Nice France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5056-219X","authenticated-orcid":false,"given":"Manon","family":"Blaise","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of C\u00f4te d'Azur, Centre Hospitalier Universitaire de Nice (CHU)  Nice France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7243-0606","authenticated-orcid":false,"given":"Hanene","family":"Bzioueche","sequence":"additional","affiliation":[{"name":"University of C\u00f4te d'Azur, C3M, INSERM U1065  Nice France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1842-6411","authenticated-orcid":false,"given":"Marie","family":"Irondelle","sequence":"additional","affiliation":[{"name":"University of C\u00f4te d'Azur, C3M, INSERM U1065  Nice France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4428-1222","authenticated-orcid":false,"given":"Katia","family":"Boniface","sequence":"additional","affiliation":[{"name":"University of Bordeaux, CNRS, Immuno ConcEpT, UMR 5164  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2661-2369","authenticated-orcid":false,"given":"Meri K.","family":"Tulic","sequence":"additional","affiliation":[{"name":"University of C\u00f4te d'Azur, C3M, INSERM U1065  Nice France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0797-6570","authenticated-orcid":false,"given":"Thierry","family":"Passeron","sequence":"additional","affiliation":[{"name":"University of C\u00f4te d'Azur, C3M, INSERM U1065  Nice France"},{"name":"Department of Dermatology University of C\u00f4te d'Azur, Centre Hospitalier Universitaire de Nice (CHU)  Nice France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"crossref","first-page":"e386","DOI":"10.1016\/S2468-2667(24)00026-4","article-title":"Estimating the burden of vitiligo: a systematic review and modelling study","volume":"9","author":"Akl J","year":"2024","journal-title":"Lancet Public Health"},{"key":"e_1_2_14_3_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.613056","article-title":"Targeting innate immunity to combat cutaneous stress: the vitiligo perspective","volume":"12","author":"Boniface K","year":"2021","journal-title":"Front Immunol"},{"key":"e_1_2_14_4_1","doi-asserted-by":"crossref","DOI":"10.1172\/JCI185785","article-title":"Recent clinical and mechanistic insights into vitiligo offer new treatment options for cell\u2010specific autoimmunity","volume":"135","author":"Ezzedine K","year":"2025","journal-title":"J Clin Invest"},{"key":"e_1_2_14_5_1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41572-025-00670-x","article-title":"Vitiligo","volume":"11","author":"Seneschal J","year":"2025","journal-title":"Nat Rev Dis Primers"},{"key":"e_1_2_14_6_1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0140-6736(20)30747-9","article-title":"First step in a new era for treatment of patients with vitiligo","volume":"396","author":"Passeron T","year":"2020","journal-title":"Lancet"},{"key":"e_1_2_14_7_1","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1038\/jid.2015.126","article-title":"Narrow band ultraviolet B treatment for human vitiligo is associated with proliferation, migration, and differentiation of melanocyte precursors","volume":"135","author":"Goldstein NB","year":"2015","journal-title":"J Invest Dermatol"},{"key":"e_1_2_14_8_1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/pcmr.12561","article-title":"Repigmentation in vitiligo: position paper of the vitiligo global issues consensus conference","volume":"30","author":"Gan EY","year":"2017","journal-title":"Pigment Cell Melanoma Res"},{"key":"e_1_2_14_9_1","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/med.21426","article-title":"Trends in regenerative medicine: Repigmentation in vitiligo through melanocyte stem cell mobilization","volume":"37","author":"Birlea SA","year":"2017","journal-title":"Med Res Rev"},{"key":"e_1_2_14_10_1","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/jid.2014.527","article-title":"Maintenance therapy of adult vitiligo with 0.1% tacrolimus ointment: a randomized, double blind, placebo\u2010controlled study","volume":"135","author":"Cavalie M","year":"2015","journal-title":"J Invest Dermatol"},{"key":"e_1_2_14_11_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.652191","article-title":"Resident memory T cells in autoimmune skin diseases","volume":"12","author":"Ryan GE","year":"2021","journal-title":"Front Immunol"},{"key":"e_1_2_14_12_1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jid.2017.08.038","article-title":"Vitiligo skin is imprinted with resident memory CD8 T cells expressing CXCR3","volume":"138","author":"Boniface K","year":"2018","journal-title":"J Invest Dermatol"},{"key":"e_1_2_14_13_1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1126\/scitranslmed.aam7710","article-title":"Antibody blockade of IL\u201015 signaling has the potential to durably reverse vitiligo","volume":"10","author":"Richmond JM","year":"2018","journal-title":"Sci Transl Med"},{"key":"e_1_2_14_14_1","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.jid.2015.12.040","article-title":"Development and validation of the vitiligo extent score (VES): an international collaborative initiative","volume":"136","author":"Geel N","year":"2016","journal-title":"J Invest Dermatol"},{"key":"e_1_2_14_15_1","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jaad.2017.11.032","article-title":"Validation study of the vitiligo extent score\u2010plus","volume":"78","author":"Geel N","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_14_16_1","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/bjd.18950","article-title":"Reliability and validity of the vitiligo signs of activity score (VSAS)","volume":"183","author":"Geel N","year":"2020","journal-title":"Br J Dermatol"},{"key":"e_1_2_14_17_1","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology life quality index (DLQI)\u2010\u2010a simple practical measure for routine clinical use","volume":"19","author":"Finlay AY","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"e_1_2_14_18_1","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.it.2019.07.004","article-title":"Opening the window of immune opportunity: treating childhood asthma","volume":"40","author":"Lloyd CM","year":"2019","journal-title":"Trends Immunol"},{"key":"e_1_2_14_19_1","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.jid.2021.11.018","article-title":"Applying early intervention strategies to autoimmune skin diseases. Is the window of opportunity preclinical? A Dermato\u2010rheumatology perspective","volume":"142","author":"Carter LM","year":"2022","journal-title":"J Invest Dermatol"},{"key":"e_1_2_14_20_1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00415-023-11969-8","article-title":"Multiple sclerosis: time for early treatment with high\u2010efficacy drugs","volume":"271","author":"Selmaj K","year":"2024","journal-title":"J Neurol"},{"key":"e_1_2_14_21_1","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41584-024-01107-7","article-title":"Joint\u2010specific memory, resident memory T cells and the rolling window of opportunity in arthritis","volume":"20","author":"Chang MH","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"e_1_2_14_22_1","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamadermatol.2024.2463","article-title":"Noninferiority of 16\u2010week vs 8\u2010week Guselkumab dosing in super responders for maintaining control of psoriasis: the GUIDE randomized clinical trial","volume":"160","author":"Eyerich K","year":"2024","journal-title":"JAMA Dermatol"},{"key":"e_1_2_14_23_1","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/jdv.18846","article-title":"Secukinumab demonstrates superiority over narrow\u2010band ultraviolet B phototherapy in new\u2010onset moderate to severe plaque psoriasis patients: week 52 results from the STEPIn study","volume":"37","author":"Iversen L","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_14_24_1","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15219","article-title":"Early localized vitiligo, a medical emergency: long\u2010term follow\u2010up study","volume":"35","author":"Esmat SM","year":"2022","journal-title":"Dermatol Ther"},{"key":"e_1_2_14_25_1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/bjd.17150","article-title":"Addition of oral minipulse dexamethasone to narrowband ultraviolet B phototherapy and topical steroids helps arrest disease activity in patients with vitiligo","volume":"180","author":"Tovar\u2010Garza A","year":"2019","journal-title":"Br J Dermatol"},{"key":"e_1_2_14_26_1","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jdermsci.2012.01.012","article-title":"The effects of NB\u2010UVB on the hair follicle\u2010derived neural crest stem cells differentiating into melanocyte lineage in\u00a0vitro","volume":"66","author":"Dong D","year":"2012","journal-title":"J Dermatol Sci"},{"key":"e_1_2_14_27_1","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/1523-1747.ep12476645","article-title":"Presence or absence of melanocytes in vitiligo lesions: an immunohistochemical investigation","volume":"100","author":"LePoole C","year":"1993","journal-title":"J Invest Dermatol"},{"key":"e_1_2_14_28_1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1346-8138.1992.tb03211.x","article-title":"Epidermal changes in active vitiligo","volume":"19","author":"Hann SK","year":"1992","journal-title":"J Dermatol"},{"key":"e_1_2_14_29_1","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1111\/jdv.19451","article-title":"Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the international vitiligo task force part 1: towards a new management algorithm","volume":"37","author":"Geel N","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70748","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.70748","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70748","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T08:53:04Z","timestamp":1790326384000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.70748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":28,"alternative-id":["10.1111\/jdv.70748"],"URL":"https:\/\/doi.org\/10.1111\/jdv.70748","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"assertion":[{"value":"2026-05-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"jdv.70748"}}